Gene · 886
CCKAR: cholecystokinin A receptor
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. CCKAR: cholecystokinin A receptor. Genes, record 886. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/886
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P32238 | Cholecystokinin receptor type A | 428 | 14 | Ensembl, GeneID, HGNC |
Source UniProt
Patents33
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 41193 | P32238 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 754 | P32238 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 754 | P32238 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 14980 | P32238 | Espacenet |
| US 11400116 B2 | 2022-08-02 | 216 | P32238 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 117951 | P32238 | Espacenet |
| US 11078247 B2 | 2021-08-03 | 1712 | P32238 | Espacenet |
| US 10772934 B2 | 2020-09-15 | 990 | P32238 | Espacenet |
| US 10292374 B2 | 2019-05-21 | 316 | P32238 | Espacenet |
| JP 2019054813 A | 2019-04-11 | 221628 | P32238 | Espacenet |
1 to 10 of 33
See all 33 patentsDrugs6
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| CE-326597 | CHEMBL1269258 | Cholecystokinin A receptor agonist | AGONIST | ChEMBL |
| CERULETIDE | CHEMBL1201355 | Cholecystokinin A receptor agonist | AGONIST | ChEMBL |
| CERULETIDE DIETHYLAMINE | CHEMBL1200755 | Cholecystokinin A receptor agonist | AGONIST | ChEMBL |
| DEXLOXIGLUMIDE | CHEMBL550781 | Cholecystokinin A receptor antagonist | ANTAGONIST | ChEMBL |
| PROGLUMIDE | CHEMBL316561 | Cholecystokinin receptor antagonist | ANTAGONIST | ChEMBL |
| SINCALIDE | CHEMBL1121 | Cholecystokinin A receptor agonist | AGONIST | ChEMBL |
Trials6
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT06017323 | PROGLUMIDE | PHASE1 | ClinicalTrials.gov | |
| NCT05827055 | PROGLUMIDE | PHASE2 | ClinicalTrials.gov | |
| NCT05551858 | PROGLUMIDE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT04152473 | PROGLUMIDE | PHASE1 | ClinicalTrials.gov | |
| NCT00542009 | CE-326597 | PHASE2 | ClinicalTrials.gov | |
| NCT00220090 | DEXLOXIGLUMIDE | PHASE3 | ClinicalTrials.gov |
NIH grants613
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | CCKAR papers | Newest fiscal year |
|---|---|---|---|
| P30CA051008 | Georgetown University Lombardi Comprehensive Cancer Center Support Grant | 7 | 2025 |
| P30CA056036 | Translational Research in Cancer | 5 | 2025 |
| ZIADK053100 | Characterization And Pharmacology Of Receptors For Gastrointestinal Peptides | 5 | 2025 |
| T32GM008562 | Clinical Pharmacology Training Program | 4 | 2025 |
| ZIADK053101 | Cellular Basis Of Action Of Gastrointestinal Peptides/Growth factors | 4 | 2025 |
| R01DA036596 | Regulation of Neuronal GPCR Signaling | 3 | 2025 |
| P30DK017047 | Diabetes Research Center | 2 | 2025 |
| P30DK084567 | Mayo Center for Cell Signaling in Gastroenterology | 2 | 2025 |
| P60AA006420 | CNS Effects of Alcohol: Cellular Neurobiology | 2 | 2025 |
| R01GM129325 | ChimeraX -- Next Generation Visualization and Analysis Software for Multiscale Modeling | 2 | 2025 |
1 to 10 of 613Source NIH's project files
See all 613 nih grantsPapers1,123
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Integrative network pharmacology, transcriptomics, and molecular docking identify candidate Centella asiatica constituents and targets in neurodegenerative diseases. | PLoS One | 2026 | 42536688 | PubTator, text mining | PubMed |
| Heart-Specific Spinal and Vagal Afferents: Transcriptomic Signatures and Optogenetically Modulated Functional Coupling With Cardiomyocytes. | Compr Physiol | 2026 | 42381253 | PubTator, text mining | PubMed |
| Molecular Characterization of Small Extracellular Vesicles in Pancreatic Cancer Patients Treated with Neoadjuvant Chemotherapy Followed by Stereotactic Body Radiation. | Cancers (Basel) | 2026 | 42279288 | PubTator, text mining | PubMed |
| Nmur1 and Cckar fail to support functional genetic access in adult dopamine neurons and challenge GPCR atlas assignments. | bioRxiv | 2026 | 42182265 | PubTator, text mining | PubMed |
| Peripheral cholecystokinin promotes thermogenesis via vagal afferent signalling, hypothalamic oxytocin and sympathetic outflow to brown adipose tissue. | J Physiol | 2026 | 42120179 | PubTator, text mining | PubMed |
| Cholecystokinin A Receptor Knockdown Diminishes Colon Cancer Cell Invasive Potential via Modulation of Integrin/FAK, EMT, and uPA/uPAR/MMP2 Axis. | Oncol Res | 2026 | 41930160 | PubTator, text mining | PubMed |
| Glucose Intake during the Neonatal Period Modulates the Central Melanocortin System with Breed-Specific Differences. | J Poult Sci | 2026 | 41799539 | PubTator, text mining | PubMed |
| Exploring the Pain-Relieving Potential: Unveiling Antinociceptive Properties in Animal Venoms and Toxins. | Toxins (Basel) | 2026 | 41745735 | PubTator, text mining | PubMed |
| Personalized Treatments for Functional Disorders of the Sphincter of Oddi: A Short Muscle with a Long History of Discussion and Controversies. | J Pers Med | 2026 | 41745397 | PubTator, text mining | PubMed |
| Comparison of receptor expression and cholecystokinin signaling between left and right nodose ganglia. | Am J Physiol Cell Physiol | 2026 | 41661036 | PubTator, text mining | PubMed |
1 to 10 of 1,123
See all 1,123 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/886
GET https://conductscience.org/api/genes/v1/886/patents?page=2